ArticleBMJ open2025

Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care.

Nicolas Danchin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.